Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Tharimmune Inc (NASDAQ:THAR) reported positive Phase 1 data for TH104, a transmucosal buccal film, showing higher bioavailability and similar pharmacokinetics compared to a European tablet. The studies indicated potential benefits for patients with impaired liver function and consistent safety profiles. The company plans to discuss Phase 2 trial design with the FDA and expects topline data in 2024 for treating chronic pruritis in primary biliary cholangitis patients. THAR's stock price surged 50% to $4.32.
November 27, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune Inc's stock price rose 50% after reporting positive Phase 1 data for TH104, indicating higher bioavailability and safety for liver-impaired patients, with Phase 2 discussions with the FDA planned.
The positive Phase 1 trial results for TH104 suggest a strong potential for the drug, especially for patients with liver impairments. The stock's significant rise reflects investor optimism about the drug's prospects and the upcoming FDA discussions for the Phase 2 trial. The news is highly relevant and important to THAR as it directly pertains to the company's lead product and its future revenue potential. The confidence score is high due to the clear positive outcome of the trial and the stock's immediate reaction.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100